HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.8.1
  1. Home
  2. /Compound

Fadrozole

HCID 59693
New reaction
Print

Completing data — refresh the page later to see the latest

Basic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Substructure searchFind similar structures

Basic information

CAS
102676-47-1
Standard SMILES
N#Cc1ccc(C2CCCc3cncn32)cc1
InChIKey
CLPFFLWZZBQMAO-UHFFFAOYSA-N
Molecular formula
C14H13N3
Average molar mass
223.27 g/mol
Monoisotopic mass
223.11094743

Overview

4-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl)benzonitrile is an imidazopyridine.

Names & identifiers

Preferred name
Fadrozole
IUPAC
4-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl)benzonitrile
English name
FADROZOLE
Molecular formula
C14H13N3
Molecular weight
223.27

Names & synonyms

FADROZOLE102676-47-14-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl)benzonitrileFadrozolFadrozolumBenzonitrile, 4-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl)-DTXSID5034141H3988M64PUCGS020286ABenzonitrile, 4-(5,6,7,8-tetrahydroimidazo(1,5-a)pyridin-5-yl)-CGS16949A4-(5,6,7,8-Tetrahydroimidazo(1,5-a)pyridin-5-yl)benzonitrile
Show more names
AfemaCS-2710FAD 286)CGS-16949CGS-169494FADROZOLE USP/EP/BPFadrozole (CGS 16949AFadrozole, 10 mM in DMSO
4-(5,6,7,8-tetrahydroimidazo(5,1-f)pyridin-5-yl)benzonitrile4-(5,6,7,8-tetrahydroimidazo[5,1-f]pyridin-5-yl)benzonitrileFAD286CGS-020286ARefChem:597144DTXCID3014141FAD-286Fadrozole [INN]

Database identifiers

CAS
102676-47-1
PubChem CID
59693
DTXSID
DTXSID5034141
ChEMBL
CHEMBL9298
ChEBI
CHEBI:94355
UNII
H3988M64PU
EC Number
862-508-6
Nikkaji
J366.696D

Properties

Computed structural propertiesFilling in

XLogP
2.1
Topological polar surface area
41.6 Ų
Hydrogen bond donors
0
Hydrogen bond acceptors
2
Rotatable bonds
1
Heavy atoms
17
Formal charge
0
Complexity
311

Experimental & physicochemical properties

Chemical ClassesPharmaceutical
Endocrine DisruptorsPotential endocrine disrupting compound
Collision Cross Section157.2 Ų [M+H]+ [CCS Type: DT; Buffer gas: N2; Ionization: ESI+; Dataset: TOXCAST; Source Identifier: DTXSID4020618]

Physicochemical properties

Melting point
0 °C · 0°C
Boiling point
0 °C · 0°C
Density
1.2 · 1.20
Flash point
0 °C · 0°C
storage temp.
2 · 2-8°C
solubility
100 mg/mL · DMSO : ≥ 100 mg/mL (447.89 mM)
form
Solid
pka
7.16 · 7.16±0.40(Predicted)
color
White to off-white
FDA UNII
3988 M64PU · H3988M64PU

Safety & regulation

Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.

GHS classification

GHS Classification · 4 items

Warning

H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]

P261, P264, P264+P265, P270, P271, P280, P301+P317, P302+P352, P304+P340, P305+P351+P338, P317, P319, P321, P330, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)

The GHS information provided by 1 company from 1 notification to the ECHA C&L Inventory.

Hazard information

Hazard Classes and CategoriesAcute Tox. 4 (100%)

Toxicology

USGS Health-Based Screening Levels for Evaluating Water-Quality · 3 items

Fadrozole

Pharmaceutical

Smith, C.D. and Nowell, L.H., 2024. Health-Based Screening Levels for evaluating water-quality data (3rd ed.). DOI:10.5066/F71C1TWP

Safety data

ridadr
3439
risk_code
20/21/22
Signal word
Danger
Symbol(GHS)
GHS06,GHS08
safety_code
22-24/25
Hazard statements
H301-H361
Precautionary statements
P281-P301+P310

Chemistry & industry

Pharmacology

MeSH Pharmacological Classification · 3 items

Compounds which inhibit or antagonize the action or biosynthesis of estrogenic compounds.

Antineoplastic agents that are used to treat hormone-sensitive tumors. Hormone-sensitive tumors may be hormone-dependent, hormone-responsive, or both. A hormone-dependent tumor regresses on removal of the hormonal stimulus, by surgery or pharmacological block. Hormone-responsive tumors may regress when pharmacologic amounts of hormones are administered regardless of whether previous signs of hormone sensitivity were observed. The major hormone-responsive cancers include carcinomas of the breast, prostate, and endometrium; lymphomas; and certain leukemias. (From AMA Drug Evaluations Annual 1994, p2079)

Compounds that inhibit AROMATASE in order to reduce production of estrogenic steroid hormones.

Applications

UsesAntineoplastic

Upstream & downstream products

Upstream raw materials

Concentrated sulfuric acid

Additional notes

DefinitionChEBI: 4-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl)benzonitrile is an imidazopyridine.

Related reactions

49 records
New reaction record
HRID 22546 reaction equation
HRID 22546As productuspto-grants-1995_06
HRID 22547 reaction equation
HRID 22547As productuspto-grants-1995_06
HRID 22548 reaction equation
HRID 22548As productuspto-grants-1995_06
HRID 22551 reaction equation
HRID 22551As productuspto-grants-1995_06
HRID 22554 reaction equation
HRID 22554As reactantuspto-grants-1995_06
HRID 22555 reaction equation
HRID 22555As productuspto-grants-1995_06
HRID 22558 reaction equation
HRID 22558As productuspto-grants-1995_06
HRID 22566 reaction equation
HRID 22566As reactantuspto-grants-1995_06
PreviousPage 1 of 7

Compound notes

On this pageBasic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
EPA Substance Registry System
4 · Benzonitrile, 4-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl)- (102676-47-1)
Symbol(GHS)
6 · GHS06,GHS08
Signal word
Danger
Hazard statements
301 · H301-H361
Precautionary statements
281 · P281-P301+P310
Risk Statements
20 · 20/21/22
Safety Statements
22 · 22-24/25
RIDADR
3439 · 3439